Inga Drossart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Inga Drossart has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Archana Rao
Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool L14 3PE, UK
3 shared publications - Haran Burri
Cardiac Pacing Unit, Department of Cardiology, University Hospital of Geneva , Geneva
3 shared publications - Kevin Vernooy
Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center , Maastricht
3 shared publications - Alan Gordon Fraser
Cardiff University
2 shared publications - Carsten Walter Israel
Klinik für Innere Medizin – Kardiologie, Diabetologie & Nephrologie, Evangelisches Klinikum Bethel, Bielefeld, Deutschland
2 shared publications - Daniel Keene
National Heart and Lung Institute, Imperial College London , London
2 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (1)
Catheter Ablation of atrial fibrillation vs. atrioventricular nodal ablation with Conduction system pacing in persistent atrial fibrillation and heart failure (ABACUS): rationale and design
Aims: Patients with persistent atrial fibrillation (AF) and heart failure (HF) have compromised clinical outcomes. Contemporary management includes rhythm control with AF ablation, or rate control and regularization with conduction system pacing and atrioventricular nodal ablation (CSP + AVNA). These strategies have never been compared in a randomized clinical trial. The study aims to determine whether CSP + AVNA is superior to AF ablation for reducing all-cause mortality and cardiovascular hospitalization, and noninferior with respect to all-cause mortality and heart failure hospitalization. Methods and results: ABACUS is a multicentre, investigator-initiated, randomized controlled trial enrolling 220 patients with persistent AF and HF, aged >60 years, who are eligible for both treatment modalities, with at most one previous AF ablation procedure. Participants will be randomized 1:1 to either catheter ablation of AF (with pulmonary vein isolation using any routine technique) or to CSP + AVNA. All patients will undergo at least one year of follow-up. The co-primary endpoints will be tested sequentially. A number of predefined secondary endpoints, including costs, will also be evaluated. Discussion: ABACUS compares CSP + AVNA with AF ablation in patients with persistent AF and HF. The results will provide evidence to improve care in this vulnerable patient population.
- 6 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (1)
Open AccessCatheter Ablation of atrial fibrillation vs. atrioventricular nodal ablation with Conduction system pacing in persistent atrial fibrillation and heart failure (ABACUS): rationale and design
Aims: Patients with persistent atrial fibrillation (AF) and heart failure (HF) have compromised clinical outcomes. Contemporary management includes rhythm control with AF ablation, or rate control and regularization with conduction system pacing and atrioventricular nodal ablation (CSP + AVNA). These strategies have never been compared in a randomized clinical trial. The study aims to determine whether CSP + AVNA is superior to AF ablation for reducing all-cause mortality and cardiovascular hospitalization, and noninferior with respect to all-cause mortality and heart failure hospitalization. Methods and results: ABACUS is a multicentre, investigator-initiated, randomized controlled trial enrolling 220 patients with persistent AF and HF, aged >60 years, who are eligible for both treatment modalities, with at most one previous AF ablation procedure. Participants will be randomized 1:1 to either catheter ablation of AF (with pulmonary vein isolation using any routine technique) or to CSP + AVNA. All patients will undergo at least one year of follow-up. The co-primary endpoints will be tested sequentially. A number of predefined secondary endpoints, including costs, will also be evaluated. Discussion: ABACUS compares CSP + AVNA with AF ablation in patients with persistent AF and HF. The results will provide evidence to improve care in this vulnerable patient population.
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Cardiac implantable electronic device upgrades and downgrades: a Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS)
Cardiac implantable electronic device upgrade and downgrade procedures are increasingly being performed. Whilst the most appropriate guideline-recommended device may have been followed during a patient's initial procedure, the requirements of patients can change over time. This could be due to worsening of cardiac function due to detrimental effects of pacing itself or the diagnosis, development, or progression of another cardiac comorbidity. Device downgrades are also performed when a patient's clinical state changes and are often considered in patients with increased frailty and comorbidity. This clinical consensus statement aims to provide a framework for screening patients for device upgrade, pre-procedural planning considerations, available procedural strategies, namely a summary of techniques and approaches for vascular access, including ipsilateral and contralateral options, and a framework for when extraction to gain access may be appropriate. The document also provides advice on how to frame an ethical discussion with patients and carers on available options.
- 1 December 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Open AccessCardiac implantable electronic device upgrades and downgrades: a Clinical Consensus Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS)
Cardiac implantable electronic device upgrade and downgrade procedures are increasingly being performed. Whilst the most appropriate guideline-recommended device may have been followed during a patient's initial procedure, the requirements of patients can change over time. This could be due to worsening of cardiac function due to detrimental effects of pacing itself or the diagnosis, development, or progression of another cardiac comorbidity. Device downgrades are also performed when a patient's clinical state changes and are often considered in patients with increased frailty and comorbidity. This clinical consensus statement aims to provide a framework for screening patients for device upgrade, pre-procedural planning considerations, available procedural strategies, namely a summary of techniques and approaches for vascular access, including ipsilateral and contralateral options, and a framework for when extraction to gain access may be appropriate. The document also provides advice on how to frame an ethical discussion with patients and carers on available options.
- Top Cited PapersOpen Access
- 28 March 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (4)
European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society
Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing. Since the 2021 European Society of Cardiology pacing guidelines, there has been growing evidence that this therapy is safe and effective. Furthermore, left bundle branch area pacing was not covered in these guidelines due to limited evidence at that time. This Clinical Consensus Statement provides advice on indications for CSP, taking into account the significant evolution in this domain.
- 28 March 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (4)
Top Cited PapersOpen AccessEuropean Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society
Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing. Since the 2021 European Society of Cardiology pacing guidelines, there has been growing evidence that this therapy is safe and effective. Furthermore, left bundle branch area pacing was not covered in these guidelines due to limited evidence at that time. This Clinical Consensus Statement provides advice on indications for CSP, taking into account the significant evolution in this domain.
- 20 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (16) , 1469-1479
Priorities for medical device regulatory approval: a report from the European Society of Cardiology Cardiovascular Round Table
The European Union (EU) Medical Device Regulation increased regulatory scrutiny to improve the safety and performance of new medical devices. An equally important goal is providing timely access to innovative devices to benefit patient care. The European Society of Cardiology strongly advocates for the evolution of the Medical Device Regulation system to facilitate priority access for innovative devices for unmet needs and orphan cardiovascular (CV) medical devices in EU countries. Although device approval is currently executed by Notified Bodies in the EU, it will be advantageous in the mid-term to consider a single EU regulatory agency for devices. In the short term, steps can be taken to transform the current system into a more efficient, predictable, cost-effective, and user-friendly service. Key strategies include the following: enhancing predictability of the approval process through use of early scientific advice from regulators; establishing unique regulatory pathways for CV orphan, paediatric, and innovative devices; promoting more efficient (re)certification of essential legacy CV devices; improving transparency of sponsor interactions with Notified Bodies; expanding the roles of the Expert Panels to assist in the approval of CV devices; promoting global regulatory harmonization, considering streamlined authorization of CV medical technologies across selected jurisdictions; developing an efficient system to monitor device safety; and ensuring funding for data collection platforms. Some strategies that could help include considering a pilot programme for joint approval processes of selected devices in partnership with other regions (i.e. US Food and Drug Administration); developing priority pathways for accelerated access to innovative or orphan devices; and increasing recognition of the importance of early feasibility studies in the EU.
- 20 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (16) , 1469-1479
Priorities for medical device regulatory approval: a report from the European Society of Cardiology Cardiovascular Round Table
The European Union (EU) Medical Device Regulation increased regulatory scrutiny to improve the safety and performance of new medical devices. An equally important goal is providing timely access to innovative devices to benefit patient care. The European Society of Cardiology strongly advocates for the evolution of the Medical Device Regulation system to facilitate priority access for innovative devices for unmet needs and orphan cardiovascular (CV) medical devices in EU countries. Although device approval is currently executed by Notified Bodies in the EU, it will be advantageous in the mid-term to consider a single EU regulatory agency for devices. In the short term, steps can be taken to transform the current system into a more efficient, predictable, cost-effective, and user-friendly service. Key strategies include the following: enhancing predictability of the approval process through use of early scientific advice from regulators; establishing unique regulatory pathways for CV orphan, paediatric, and innovative devices; promoting more efficient (re)certification of essential legacy CV devices; improving transparency of sponsor interactions with Notified Bodies; expanding the roles of the Expert Panels to assist in the approval of CV devices; promoting global regulatory harmonization, considering streamlined authorization of CV medical technologies across selected jurisdictions; developing an efficient system to monitor device safety; and ensuring funding for data collection platforms. Some strategies that could help include considering a pilot programme for joint approval processes of selected devices in partnership with other regions (i.e. US Food and Drug Administration); developing priority pathways for accelerated access to innovative or orphan devices; and increasing recognition of the importance of early feasibility studies in the EU.
- 3 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (3) , 227-228
Six years strong: the transformative journey of the European Society of Cardiology Patient Forum
- 3 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (3) , 227-228
Six years strong: the transformative journey of the European Society of Cardiology Patient Forum
- Open Access
- 16 February 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (13) , 1104-1115
Device innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table
Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence and machine learning. There is a need to foster an environment conducive to medical technology development and validation so that Europe can continue to play a major role in device innovation while providing high standards of safety. This paper summarizes viewpoints on the topic of device innovation in cardiovascular medicine at the European Society of Cardiology Cardiovascular Round Table, a strategic forum for high-level dialogue to discuss issues related to the future of cardiovascular health in Europe. Devices are developed and improved through an iterative process throughout their lifecycle. Early feasibility studies demonstrate proof of concept and help to optimize the design of a device. If successful, this should ideally be followed by randomized clinical trials comparing novel devices vs. accepted standards of care when available and the collection of post-market real-world evidence through registries. Unfortunately, standardized procedures for feasibility studies across various device categories have not yet been implemented in Europe. Cardiovascular imaging can be used to diagnose and characterize patients for interventions to improve procedural results and to monitor devices long term after implantation. Randomized clinical trials often use cardiac imaging-based inclusion criteria, while less frequently trials randomize patients to compare the diagnostic or prognostic value of different modalities. Applications using machine learning are increasingly important, but specific regulatory standards and pathways remain in development in both Europe and the USA. Standards are also needed for smart devices and digital technologies that support device-driven biomonitoring. Changes in device regulation introduced by the European Union aim to improve clinical evidence, transparency, and safety, but they may impact the speed of innovation, access, and availability. Device development programmes including dialogue on unmet needs and advice on study designs must be driven by a community of physicians, trialists, patients, regulators, payers, and industry to ensure that patients have access to innovative care.
- 16 February 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (13) , 1104-1115
Open AccessDevice innovation in cardiovascular medicine: a report from the European Society of Cardiology Cardiovascular Round Table
Research performed in Europe has driven cardiovascular device innovation. This includes, but is not limited to, percutaneous coronary intervention, cardiac imaging, transcatheter heart valve implantation, and device therapy of cardiac arrhythmias and heart failure. An important part of future medical progress involves the evolution of medical technology and the ongoing development of artificial intelligence and machine learning. There is a need to foster an environment conducive to medical technology development and validation so that Europe can continue to play a major role in device innovation while providing high standards of safety. This paper summarizes viewpoints on the topic of device innovation in cardiovascular medicine at the European Society of Cardiology Cardiovascular Round Table, a strategic forum for high-level dialogue to discuss issues related to the future of cardiovascular health in Europe. Devices are developed and improved through an iterative process throughout their lifecycle. Early feasibility studies demonstrate proof of concept and help to optimize the design of a device. If successful, this should ideally be followed by randomized clinical trials comparing novel devices vs. accepted standards of care when available and the collection of post-market real-world evidence through registries. Unfortunately, standardized procedures for feasibility studies across various device categories have not yet been implemented in Europe. Cardiovascular imaging can be used to diagnose and characterize patients for interventions to improve procedural results and to monitor devices long term after implantation. Randomized clinical trials often use cardiac imaging-based inclusion criteria, while less frequently trials randomize patients to compare the diagnostic or prognostic value of different modalities. Applications using machine learning are increasingly important, but specific regulatory standards and pathways remain in development in both Europe and the USA. Standards are also needed for smart devices and digital technologies that support device-driven biomonitoring. Changes in device regulation introduced by the European Union aim to improve clinical evidence, transparency, and safety, but they may impact the speed of innovation, access, and availability. Device development programmes including dialogue on unmet needs and advice on study designs must be driven by a community of physicians, trialists, patients, regulators, payers, and industry to ensure that patients have access to innovative care.
- Open Access
- 16 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (2) , 79-80
Disparity in diagnosis and treatment of cardiovascular disease in women: a call to joint action from the European Society of Cardiology Patient Forum
Cardiovascular disease (CVD) is the leading cause of death in women worldwide1 but remains understudied, under-recognised, underdiagnosed, and undertreated.
- 16 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (2) , 79-80
Open AccessDisparity in diagnosis and treatment of cardiovascular disease in women: a call to joint action from the European Society of Cardiology Patient Forum
Cardiovascular disease (CVD) is the leading cause of death in women worldwide1 but remains understudied, under-recognised, underdiagnosed, and undertreated.
- 15 June 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (28) , 2506-2507
The essential role of patients in advocacy and policy
- 15 June 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (28) , 2506-2507
The essential role of patients in advocacy and policy
- Open Access
- 24 September 2022
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 66 (4) , 831-832
Innovations in EP: the thin line between taking chances and taking (unknown) risks—a patient’s perspective
- 24 September 2022
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 66 (4) , 831-832
Open AccessInnovations in EP: the thin line between taking chances and taking (unknown) risks—a patient’s perspective
- Open Access
- 25 August 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (11) , 1713-1715
The ‘myrhythmdevice.org’ educational website for patients with implanted cardiac devices from the European Heart Rhythm Association
The implantation rate of cardiovascular implantable electronic devices (CIED) is steadily increasing.1 The ageing population, the increasing life expectancy, and the technological developments of the last decades have turned the CIED to everyday clinical praxis. Cardiovascular implantable electronic devices are more accessible than ever, and the variety of types and models is large. The choice of the right device is crucial, as it may have significant impact in patients’ private and professional life, but the decision process is not always clear. Hence, active participation of patients on decisions regarding their CIED is important.
- 25 August 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (11) , 1713-1715
Open AccessThe ‘myrhythmdevice.org’ educational website for patients with implanted cardiac devices from the European Heart Rhythm Association
The implantation rate of cardiovascular implantable electronic devices (CIED) is steadily increasing.1 The ageing population, the increasing life expectancy, and the technological developments of the last decades have turned the CIED to everyday clinical praxis. Cardiovascular implantable electronic devices are more accessible than ever, and the variety of types and models is large. The choice of the right device is crucial, as it may have significant impact in patients’ private and professional life, but the decision process is not always clear. Hence, active participation of patients on decisions regarding their CIED is important.